Literature DB >> 24986878

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Javier Briones1, Silvana Novelli2, José A García-Marco3, José F Tomás4, Teresa Bernal5, Carlos Grande6, Miguel A Canales7, Antonio Torres8, José M Moraleda9, Carlos Panizo10, Isidro Jarque11, Francisca Palmero12, Miguel Hernández13, Eva González-Barca14, Dulce López2, Dolores Caballero15.   

Abstract

Entities:  

Keywords:  autologous transplantation; diffuse large B-cell lymphoma; ibritumomab tiuxetan; relapse

Mesh：

Year:  2014        PMID： 24986878      PMCID： PMC4077101          DOI： 10.3324/haematol.2014.108308

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

1.  Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Authors:  Javier Briones; Silvana Novelli; José A García-Marco; José F Tomás; Teresa Bernal; Carlos Grande; Miguel A Canales; Antonio Torres; José M Moraleda; Carlos Panizo; Isidro Jarque; Francisca Palmero; Miguel Hernández; Eva González-Barca; Dulce López; Dolores Caballero
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Authors:  Avichai Shimoni; Irit Avivi; Jacob M Rowe; Moshe Yeshurun; Itai Levi; Reuven Or; Paulina Patachenko; Abraham Avigdor; Tzila Zwas; Arnon Nagler
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860
  3 in total
  3 in total

1.  Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

Authors:  Amrita Y Krishnan; Joycelynne Palmer; Auayporn P Nademanee; Robert Chen; Leslie L Popplewell; Ni-Chun Tsai; James F Sanchez; Jennifer Simpson; Ricardo Spielberger; Dave Yamauchi; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-04       Impact factor: 5.742

2.  Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.

Authors:  Alex F Herrera; Joycelynne Palmer; Vikram Adhikarla; Dave Yamauchi; Erasmus K Poku; James Bading; Paul Yazaki; Savita Dandapani; Matthew Mei; Robert Chen; Thai Cao; Nicole Karras; Pamela McTague; Auayporn Nademanee; Leslie Popplewell; Firoozeh Sahebi; John E Shively; Jennifer Simpson; D Lynne Smith; Joo Song; Ricardo Spielberger; Ni-Chun Tsai; Sandra H Thomas; Stephen J Forman; David Colcher; Anna M Wu; Jeffrey Wong; Eileen Smith
Journal:  Blood Adv       Date:  2021-12-14

Review 3.  Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.

Authors:  Sophie Auger-Quittet; Yohan Duny; Jean-Pierre Daures; Philipe Quittet
Journal:  Cancer Med       Date:  2014-04-16       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.